03/11/2026
👁️ Could gene therapy offer a new treatment option for inherited vision loss?
Laruparetigene zovaparvovec (laru-zova) is an investigational gene therapy designed to deliver functional copies of the RPGR gene to retinal cells in patients with X-linked retinitis pigmentosa (XLRP).
Why this matters:
· XLRP causes progressive vision loss, with no disease-modifying treatments currently approved by the US Food and Drug Administration (FDA).
· Laru-zova aims to restore production of RPGR protein, which is essential for photoreceptor function.
· In a late-stage clinical trial, laru-zova was reported to improve low-luminance visual acuity among patients who received a high dose.
📖 Want to know more? Explore the full story in our latest Emerging Health Care Innovation Brief. ➡️ Read the brief: https://hubs.la/Q04CWBXm0